Patent SG-11201900813R-A (SG)
Title: Fcrn antibodies and methods of use thereof
Inventor: LING LEONA
IPC: G01N33/68
Filed: 2017-07-31
Abstract: Oco O C () INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 February 2018 (01.02.2018) WIP0 I PCT omit VIII °nolo ommill 11°111°11111mm oimIE (10) International Publication Number WO 2018/023136 Al (51) International Patent Classification: C07K 16/28 (2006.01) GO1N 33/68 (2006.01) (21) International Application Number: PCT/US2017/044765 (22) International Filing Date: 31 July 2017 (31.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/368,770 29 July 2016 (29.07.2016) US 62/368,803 29 July 2016 (29.07.2016) US (71) Applicant: MOMENTA PHARMACEUTICALS, INC. [US/US]; 675 West Kendall Street, Cambridge, MA 02142 (US). (72) Inventors: LING, Leona, E.; 45 Fells Road, Winchester, MA 01890 (US). ROY, Sucharita; 7 Shakespeare Street, Tyngsboro, MA 01879 (US). WASHBURN, Nathaniel; 543 King Street, Littleton, MA 01460 (US). KEHRY, Mar- ilyn; 10440 Rock Creek Drive, San Diego, CA 92131 (US). KING, David, J.; 310 Cole Ranch Road, Encinitas, CA 92024 (US). MEADOR, James, III; 38 Gryzboska Cir- cle, Framingham, MA 01702 (US). MANNING, Anthony; 185 Hancock Street, Unit 2, Cambridge, MA 02139 (US). HILLSON, Jan; 1493 Cambridge Street, Cambridge, MA 02139-1047 (US). (74) Agent: MEIKLEJOHN, Anita L.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (54) Title: FCRN ANTIBODIES AND METHODS OF USE THEREOF (57) : The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.